Local view for "http://purl.org/linkedpolitics/eu/plenary/2001-07-03-Speech-2-164"

Predicate	Value (sorted: default)
rdf:type	lpv_eu:Speech2
dcterms:Date	"2001-07-03"^^xsd:date2
dcterms:Is Part Of	lp_eu:Question Time (Commission)2
dcterms:Language	"de"^^xsd:language2
lpv:document identification number	"en.20010703.9.2-164"2
lpv:hasSubsequent	lp_eu:2001-07-03-Speech-2-1652
lpv:speaker	lp:Paul Rübig2
lpv:spokenAs	substitute; Temporary committee on human genetics and other new technologies in modern medicine (2000-12-13--2001-11-29)3 member; EPP-ED (1999-07-20--2004-07-19)3 substitute; BUDG (1999-07-21--2002-01-14)3 vice-chair; Delegation to the EU-Slovak Republic Joint Parliamentary Committee (1999-07-22--2002-01-14)3 unknown; Österreichische Volkspartei (1999-07-20--2004-07-19)3 member; Committee on Industry, External Trade, Research and Energy (1999-07-21--2002-01-14)3
lpv:translated text	"Mr President, we all know that in the pharmaceutical world there is a very long time lag between inventing a new product and having it ready for the market, generally 10 to 12 years. The product then still has to be launched and another 20 years must elapse before third parties can manufacture it. That is why the question arises as to whether instead of resorting to patent rights and compulsory licences, it would not be better to have a development fund for such cases and to make an effort, at international level, to make a large amount of money available so that by means of bulk purchasing medicines can be made available at correspondingly low prices. Let us not forget that the selling price is a combination of manufacturing costs and licence fees. Companies would be able to supply medicines at more favourable prices if volume purchasing applied. So my question is whether the Commission could take an initiative in this area."@en1

Named graphs describing this resource:

The resource appears as object in 2 triples

Context graph